PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(12): e15167.
Published online 2010 December 6. doi:  10.1371/journal.pone.0015167
PMCID: PMC2997782

LMNA E82K Mutation Activates FAS and Mitochondrial Pathways of Apoptosis in Heart Tissue Specific Transgenic Mice

Gen Sheng Wu, Editor

Abstract

The lamin A/C (LMNA), nuclear intermediate filament proteins, is a basic component of the nuclear lamina. Mutations in LMNA are associated with a broad range of laminopathies, congenital diseases affecting tissue regeneration and homeostasis. Heart tissue specific transgenic mice of human LMNA E82K, a mutation causing dilated cardiomyopathy, were generated. LmnaE82K transgenic mouse lines exhibited thin-walled, dilated left and right ventricles, a progressive decrease of contractile function assessed by echocardiography. Abnormalities of the conduction system, myocytes disarray, collagen accumulation and increased levels of B-type natriuretic peptide (BNP), procollagen type III α1 (Col3α1) and skeletal muscle actin α1 (Actα1) were detected in the hearts of LmnaE82K transgenic mice. The LMNA E82K mutation caused mislocation of LMNA in the nucleus and swollen mitochondria with loss of critae, together with the loss of nuclear envelope integrity. Most interestingly, we found that the level of apoptosis was 8.5-fold higher in the LmnaE82K transgenic mice than that of non-transgenic (NTG) mice. In the presence of the LMNA E82K, both of FAS and mitochondrial pathways of apoptosis were activated consistent with the increase of FAS expression, the release of cytochrome c from mitochondria to cytosol and activation of caspase-8, -9 and -3. Our results suggested that the apoptosis, at least for the LMNA E82K or the mutations in the rod region of Lamin A/C, might be an important mechanism causing continuous loss of myocytes and lead to myocardial dysfunction. It could be a potential therapeutic means to suppress and/or prevent inappropriate cardiac cell death in patients carrying LMNA mutation.

Introduction

The LMNA gene is alternatively spliced to produce the two intermediate filament proteins termed nuclear lamin A/C, which locate to the nuclear lamina, a fibrous structure underlying the inner nuclear membrane [1]. Lamin A/C, emerin and complex which links the nucleoskeleton and cytoskeleton (LINC) form a variety of macro-protein complexes at the nuclear envelope and together cross-link the nuclear skeleton to the cytoskeleton. These protein complexes function to maintain nuclear architecture and stability and cellular tensegrity [2][4]. The lamins play important roles in DNA replication, chromatin organization, regulation of gene expression, spatial organization of the nuclear pore and the correct anchorage of the nuclear envelope proteins, cell development, differentiation and apoptosis [5].

The mutations in the LMNA gene has been shown to cause at least nine different autosomal recessive and dominant genetic diseases, collectively called laminopathies [6], [7]. More than 40 mutations in the LMNA gene have been shown to be involved in the severity of the cardiac symptoms, characterized by conduction defect, arrhythmias, left ventricular (LV) dysfunction, dilation with heart failure or sudden death [8][13].

Lamin A/C plays a crucial role in many cellular activities, but it is poorly understood why and how different mutants cause such diverse phenotypes in specific tissues, but other tissues are apparently unaffected [14], and the identification of the precise molecular mechanisms of LMNA mutations leading to laminopathies is also critical for developing new therapeutic strategies to prevent cardiac dysfunction and sudden death.

A novel mutation E82K in lamin A/C gene has been found to cause dilated cardiomyopathy (DCM) in a large Chinese pedigree with 50 family members [15]. In the current paper, a heart tissue specific transgenic mice expressing LMNA E82K was generated and the mechanism causing dilated cardiomyopathy for this mutation were investigated in the transgenic mice.

Results

Generation of the transgenic mice

C57BL/6J mice carrying the human LMNA E82K gene were established (Fig. 1). Two lines of LmnaE82K transgenic mice with high level of expression were selected among 53 founders by western blot analysis (Fig. 1C). The LmnaE82K transgenic mice were indistinguishable from their non-transgenic (NTG) littermates at birth and young-age. The death of the two transgenic lines occurred from 3 months old and mortality was 15.8% (3 of 19 for founder 30) and 11.1% (2 of 18 for founder 35) at 10 months of age respectively, while no death was observed in NTG mice.

Figure 1
Generation of the transgenic mice.

LmnaE82K caused dysfunction of heart in transgenic mice

Ventricular size and function of the two transgenic lines were assessed using echocardiography. The parameters of M-mode echocardiography from the NTG and LmnaE82K transgenic mice at 2, 4, 6 and 8 months of age were summarized in Table 1 and Table S1. LMNA E82K mutation significantly increased the heart to body weight ratio by 10% (Fig. 2A, n = 14, P<0.01) by gross morphology examination. The representative M-mode echocardiograms from founder 35 at 6 months of age were shown in figure 2B. To sum up, the LMNA E82K hearts exhibited thin-walled and dilated left and right ventricles when compared with NTG hearts (Table 1). LmnaE82K transgenic mice developed a progressive LV dilation and dysfunction associated with a progressive decrease of contractile function, evidenced by decreased LV percent fractional shortening (FS %) which exhibited a significance from 2 months of age compared with NTG mice (Table 1 and Table S1, P<0.01).

Figure 2
The effects of LMNA E82K on heart dimensions and hypertrophic marker expression in the transgenic mice.
Table 1
Echocardiographic characteristics of NTG and LmnaE82K transgenic mice at 6 months of age.

Electrocardiography (ECG) measurements were performed in mutant and NTG mice at 7 months of age (Table 2). Compared with WT mice, the PR interval and QRS complex duration had a tendency of increase in both of the transgenic lines, but only the mice generated from founder 35 showed a significant increase in the QRS complex duration (P<0.05) in 7 mice with ECG recording. Under light microscopy, myocyte disarray, interstitial fibrosis were observed in the LmnaE82K transgenic mice compared with the NTG mice (Fig. 2C–E). The expression level of hypertrophic markers, BNP, Actα1 and Col3α1, were obviously increased in both of the two transgenic lines compared with the NTG mice (Fig. 2F, the data from founder 35).

Table 2
ECG date for NTG and Lmna82K transgenic mice at 7 months of age.

Morphological changes of myocytes and its nucleus in the LmnaE82K transgenic mice

The immunofluorescence staining of LMNA protein indicated that LMNA E82K was mislocated in the transgenic heart instead of nuclear rim localization in the NTG heart at 7 months of age (Fig. 3A). Ultrastructural observation indicated that enlarged mitochondria and sarcoplasmic reticulum, and loss of nuclear envelope integrity due to the expression of LMNA E82K existed in the LmnaE82K mice compared with that of NTG mice (Fig. 3B and C).

Figure 3
Morphological observation.

The FAS and mitochondrial pathways of apoptosis were activated in LmnaE82K transgenic mice

Apoptosis of myocytes was detected in In situ terminal dUTP nick end-labeling (TUNEL) assay in heart tissue from LmnaE82K transgenic mice and NTG mice (Fig. 4A). The apoptotic index was increased to 5.67±2.94% in the transgenic mice while it was 0.67±1.03% in the NTG mice (Fig. 4B, n = 3, P<0.01). We found that the expression of FAS was upregulated significantly in the LmnaE82K transgenic mice (Fig. 5A, n = 3, P<0.05). The expression of procaspase-8 and the activated caspase-8 were increased 84.8% (Fig. 5A and B, n = 3, P<0.01) and 32.4% (Fig. 5A and B, n = 3, P<0.05) respectively. Meanwhile, the expression of procaspase-3 and the activated caspase-3 were 4.4-fold and 10.4-fold higher in the LmnaE82K transgenic mice than that of NTG mice (Fig. 5A and C, n = 3, P<0.001) respectively. The expression of LMNA E82K also caused the release of cytochrome c from mitochondria to cytosol, and results showed that 47% of cytochrome c in cytosolic concentrations were accompanied by decreased mitochondrial concentrations in the LmnaE82K transgenic mice (Fig. 6A and B, n = 3, P<0.001). Meanwhile, the expression of procaspase-9 and the activated caspase-9 were 2.9-fold and 13.5-fold higher in the LmnaE82K transgenic mice than that of NTG mice (Fig. 6A and C, n = 3, P<0.001) respectively. The results suggested that LMNA E82K mutation induced apoptosis in the heart is likely mediated by both of the FAS and mitochondrial pathways.

Figure 4
TUNEL assay.
Figure 5
Determination the expression of FAS and caspases.
Figure 6
Detection of cytochrome c release and activation of caspase-9.

Discussion

Mutations in the LMNA gene are the most common cause of familial dilated cardiomyopathy (FDC) showing to be the severity of the cardiac symptoms, characterized by conduction defect, arrhythmias, LV dysfunction, and dilation with heart failure or sudden death [8][13]. A few mice models has been created for lamin A/C knock out or mutations. The LMNA G608G transgenic mice targeted the expression of the Hutchinson-Gilford progeria syndrome (HGPS) mutation in keratin-5-expressing tissue led to a typical phenotype of HGPS [16]. LMNA H222P mutated gene knockin mice exhibited conduction defects, chamber dilation, increased fibrosis and lack of hypertrophy, and also showed muscular dystrophy and death at 4–9 months of age [17]. The patients with heterozygous for the LMNA E82K mutation showed clinical phenotypes of heart dilation and associated with conduction system disease at their onset age of 32 or 33 years [15]. The two LmnaE82K transgenic mice lines exhibited chamber dilation, increased heart weights, increased fibrosis, upregulation of hypertrophic maker expression, nuclear structure defects and conduction defects (Figures 1, ,2,2, ,3,3, Tables 1, ,2),2), which was similar with the phenotypes of the patients carrying the LMNA E82K mutation.

The importance of BNP as a diagnostic and therapeutic modality in cardiovascular disease is well known, it also acts as a local regulator of ventricular remodeling and a modifier of cardiac gene expression [18][20]. Actα1 is present in the developing heart and it constitutes up to 20% of the striated actin of the adult heart. Since Actα1 is a multifunctional protein that interacts with many proteins involved in folding, polymerisation, contractility and regulation of contractility, abnormal levels may affect any of those functions [21]. In the normal adult heart, approximately 2 to 4% of the myocardium is made up of collagen. The Col3α1 is one of the essential components of the cardiovascular extracellular matrix, maintaining structural and functional integrity of myocardium and thought to be responsible for abnormal myocardial stiffness and for the impaired pumping capacity of the heart [22][23]. The expression of BNP, Actα1 and Col3α1 was unregulated in the two LmnaE82K transgenic mice lines (Fig. 2F).

The death of the transgenic mice occurred from 3 months of age and the mortality of the LmnaE82K transgenic mice was about 15.8% at 10 months of age, while it showed that some patients carrying this mutation died at the age of 42 and 48 years [15], therefore the LMNA E82K mutation caused slight mortality in transgenic mice compared with other mutations of LMNA as LMNA H222P, LMNA M371K and LMNA N195K [17], [24], [25]. LMNA E82K mutation located in the coil 1B domain of central a-helical rod domain of the lamin A and the lamin C proteins, those were conserved regions of the rod domain which have been shown to play crucial roles in the assembly of intermediate filament (IF) dimers into higher order oligomers [26]. Mutations affect this region of IF proteins and may disrupt the interaction between the monomers and are linked to several diseases [27]. We observed that the assembly of the Lamin A/C was disrupted (Fig. 3A), and the integrity of the nuclear envelope was damaged (Fig. 3C) in the LmnaE82K transgenic mice. Members of the intermediate filament superfamily are critical mechanical integrators of the nuclear membrane and the cytoskeleton, protecting the cell from repeated mechanical stress. Mutations in the lamin A/C gene may cause cardiomyopathy by weakening nuclei, which increase the fragility of nuclei and could be particularly harmful to muscle cells. Forces generated during muscle contraction might potentially lead to preferential breakage of nuclei containing a defective nuclear lamina [14].

The accumulation of damaged nuclei as a result of a reduction in load-bearing properties of the nuclear lamina might be a possible mechanism of DCM [28], [29]. The alternate possibility of mechanism for the pathogenesis was the structural weakness of the lamina, which might be a predisposing factor to induce nuclear damage and apoptosis [28], [29]. In the lamin A/C knockout mice, the myocyte apoptosis was observed by 2-fold higher than that of in NTG animals [30], but we found that the level of apoptosis was 8.5-fold higher in the LmnaE82K transgenic mice than that of the NTG mice (Fig. 4A and B). We concluded that LMNA E82K mutation in mice, and probably in humans, disrupted integrity and triggered apoptosis and finally resulted in DCM and heart failure. It was possible that specialized properties of conduction system myocytes made these more susceptible than surrounding myocytes to pro-apoptotic signals triggered by mutated LMNA, and the transgenic mice may developed the conduction defects [31]. Our most interesting finding was that the expression of LMNA E82K in heart tissues increased the expression of FAS, accompanied with the activation of caspase-8 and caspase-3 in LmnaE82K transgenic mice (Fig. 5A–C). The release of cytochrome c from mitochondria to cytosol was also induced by the expression of LMNA E82K, followed the activation of caspase-9 (Fig. 6A–C).

FAS, as a member of the death receptor superfamily, plays a central role in the death receptor pathway [32]. After FAS ligand binding, FAS receptors undergo trimerization and recruit FAS-associated death domain (FADD). FAS/FADD complex binds to the initiator caspase-8. According to the cell type, activated caspase-8 may propagate the apoptotic signal either through a direct activation of executioner downstream caspases or via the release of cytochrome c from mitochondria [33][36]. The involvement of mitochondria in apoptotic processes has already been clearly demonstrated [37], [38], that the release of cytochrome c triggers the assembly of Apoptotic protease-activating factor (Apaf-1) and procaspase-9 to form an apoptosome, and procaspase-9 is then autolyticaly cleaved to active caspase-9, which then activates procaspase-3 to active caspase resulting in cleavage of its substrates and apoptosis [39], [40].

Loss of myocytes is a feature of the cardiomyopathic process that contributes to progressive decline in LV function and congestive heart failure [41], [42]. Although a number of stimuli appear to trigger the process of apoptosis in cardiomyocyte. Our results indicated that the two major signaling pathways of apoptosis: the death receptor pathway and the mitochondrial pathway were activated by the expression of LMNA E82K in heart tissue.

It has been indicated that lamin A/C regulates Wnt/β-catenin and MAPK signal pathway, and it also regulates a certain numbers of growth factors and transcription factors, like TGF-β and c-Fos, which regulates differentiation, proliferation and apoptosis in many cell types [43]. The LMNA mutations have been shown to be the severity of the cardiac symptoms, which may cause in diverse mechanisms. The apoptosis, at least for the LMNA E82K or the mutations in the rod region of Lamin A/C, might be an important mechanism causing continuous loss of myocytes and lead to myocardial dysfunction. The genetic testing of LMNA gene should be offered, because of the high risk of sudden death in these patients. It could be needed for new strategies to suppress and/or prevent inappropriate cardiac cell death in patients carrying LMNA mutation as a therapeutic means of slowing down the loss of myocytes.

Materials and Methods

Generation of the transgenic mice

The G→A substitution of LMNA cDNA (IMAGE: 2822703) that results in the E82K mutation in the protein was induced using the QuikChange site-directed mutagenesis kit (Stratagene, USA) and the sequence was confirmed by DNA sequencing. The mutated cDNA was cloned into an expression plasmid under the α-MHC promoter. The transgenic mice were generated by microinjection method [44]. Genotyping of transgenic mice was facilitated by the polymerase chain reaction (PCR) using the primers, 5′ AGAAGGAGGGTGACCTGATAG and 5′ ACCAGGTTGCTGTTCCTCT. The desired 490 bp fragment of the transgenic gene was amplified for 35 cycles at condition of 94°C for 30 s, 57°C for 30 s and 72°C for 30 s. The expression of the target gene was analyzed by western blot analysis using antibody to human LMNA (Santa Cruz). All the mice were bred in an AAALAC-accredited facility and the use of animals was approved by the Animal Care and Use Committees of The Institute of Laboratory Animal Science of Peking Union Medical College (GC08-2001).

Light and electron microscopy

For light microscopy, cardiac tissue from mice at 6 months of age was fixed in formaldehyde and mounted in paraffin blocks. Sections were stained with Hematoxylin and Eosin (H&E) or Masson trichrome. For electron microscopy, cardiac tissue was routinely fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and postfixed in 1% osmium tetroxide buffer for 1 hr. The sections were stained with uranyl acetate and lead citrate and examined under a JEM-1230 transmission electron microscope.

Echocardiography

Mice were lightly anesthetized by intraperitoneal injection of tribromoethanol at a dose of 18 ml/kg body weight. M-mode echocardiography was performed at 2, 4, 6 and 8 months of age for each transgenic mouse with a 30 MHz transducer (Vevo770, Canada) [44], [45].

Electrocardiography

Mice were fixed in the supine position on a heating pad to maintain core body temperature, and limb leads were place subcutaneously in accordance to chosen preferential derivation (lead II). Traces were recorded using a digital system (ADInstruments, USA) connected to a bioamplifier. The traces were analyzed using the LabChart software package (ADInstruments, USA) by an investigator who was blinded to the genotypes of the mice.

Reverse transcription polymerase chain reaction (RT-PCR)

Total RNA was isolated from mice heart tissues using TRIzol Reagent (Invitrogen). First-strand cDNA was synthesized according to the Superscript III reverse transcriptase manufacturer' protocol (Invitrogen). The expression level of mRNA for ANP, BNP and Col3α1 was carried out by the RT-PCR and GAPDH was used as normalization (For ANP, 5′- ATGGGCTCCTTCTCCATCAC and 5′- TTATCTTCGGTACCGGAAGCTG; For BNP, 5′- ATGGATCTCCTGAAGGTGCTGTC and 5′- CTACAACAACTTCAGTGCGTTAC; for Col3α1, 5′- GGCAGTGATGGGCAACCT and 5′- TCCCTTCGCACCGTTCTT; for GAPDH, 5′- CAAGGTCATCCATGACAACTTTG and 5′- GTCCACCACCCTGTTGCTGTAG).

Western blot

Total protein lysates from mice heart tissues were prepared by homogenizing with lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and protease inhibitor cocktail). After performing SDS-PAGE and transfer to nitrocellulose (Immobilon NC; Millipore), the membranes were incubated overnight with antibody to Lamin A/C (Santa Cruz); Actα1 (Abcam); FAS (Santa Cruz); caspase-3 (Cell Signaling); caspase-8 (Cell Signaling) or caspase-9 (Cell Signaling). After incubation with the appropriate secondary antibody for 1 h at room temperature, antibody binding was detected with a HRP-conjugated immunoglobulin G (Santa Cruz) using a chemiluminescent detection system (Westernblotting luminal reagent, Santa Cruz). GAPDH was served as normalization.

Immunofluorescence

The sections of hearts were prepared in a standard pathological procedure. The sections were dewaxed, rehydrated, unmask the epitope, blocked, then incubated with anti-lamin A/C monoclonal Ab (Santa Cruz) overnight at 4°C Sections were washed with PBS and incubated with DyLight-conjugated, affinity-purified anti-mouse IgG (KPL) for 1 hr at room temperature, and all slides were counterstained with 300 nM 4,6-diamidino-2-phenylindole (DAPI, Invitrogen). After washing with PBS, sections were mounted in ProLong Gold antifade reagent (Invitrogen). Images of the sections were collected and analyzed under confocal laser scanning microscopy (Leica TCS SP2, Germany).

TUNEL assay

TUNEL assay was performed in sections using an In Site Cell Death Detection Kit (Roche Diagnostics GmbH, Mannheim, Germany) principally according to the manufacturer's instructions. The sections of heart tissues were incubated with the TUNEL reaction mixture for 1 hr at 37°C in a dark, humidified chamber. Labeled DNA was visualized with an anti-fluorescein antibody conjugated with peroxidase (POD) using 3,3′-diaminobenzidine (DAB) as the chromogen. Sections were then washed, counterstained with hematoxylin. For negative control, TdT was omitted from the reaction mixture. Six images per heart (3 hearts per genotype group) were acquired, and positive cells were counted individually. Results were expressed as the percentage of apoptotic cells among the total cell population.

Detection of mitochondrial cytochrome c release

A whole mouse heart from mice were excised and washed in cold PBS and the cytosolic and mitochondria fractions were derived following the Mitochondrial/Cytosol Fractionation Kit manufacturer's protocol (DBI Bioscience). The cytochrome c content in cytosol and mitochondria was detected by western blot analysis using antibody to cytochrome c (Cell Signaling). GAPDH was served as normalization.

Statistical Analysis

Data was analyzed with unpaired two-tailed Student's t-tests for two groups, or one-way ANOVA for multiple groups followed by a Tukey's post hoc analysis. Data were expressed as mean ± SEM from individual experiments. Differences were considered as significant at P<0.05.

Supporting Information

Table S1

Echocardiographic characteristics of WT and LmnaE82K transgenic mice at 2, 4 and 8 months of age. LV: left ventricular; LVEDD: LV end‐diastole diameter; LVESD: LV end‐systole diameter; LVEDV: LV end‐diastolic volume; LVESV: LV end‐systole volume; LVPWD: LV posterior wall at end‐diastole; LVPWS: LV posterior wall at end‐systole; LVAWD: LV anterior wall at end‐diastole; LVAWS: LV anterior wall at end‐systole; EF%: percent ejection fraction; FS%: percent fractional shortening; HR: heart rate. *P<0.05 versus NTG mice; P<0.01 versus NTG mice; #P<0.001 versus NTG mice.

(DOC)

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported in part by the Ministry of Health Foundation (200802036) and the National Science and Technology Major Projects (2009ZX09501-026). The funders had no role in study design, date collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The nuclear lamina comes of age. Nat Rev Mol Cell Biol. 2005;6:21–31. [PubMed]
2. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest. 2004;113:370–378. [PMC free article] [PubMed]
3. Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, et al. Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol. 2006;172:41–53. [PMC free article] [PubMed]
4. Broers JL, Peeters EA, Kuijpers HJ, Endert J, Bouten CV, et al. Decreased mechanical stiffness in LMNA-/- cells is caused by defective nucleo-cytoskeletal integrity: implications for the development of laminopathies. Hum Mol Genet. 2004;13:2567–2580. [PubMed]
5. Mounkes L, Stewart CL. Structural organization and functions of the nucleus in development, aging, and disease. Curr Top Dev Biol. 2004;61:191–228. [PubMed]
6. Worman HJ, Courvalin JC. How do mutations in lamins A and C cause disease? J Clin Invest. 2004;113:349–351. [PMC free article] [PubMed]
7. Genschel J, Schmidt HH. Mutations in the LMNA gene encoding lamin A/C. Hum Mutat. 2000;16:451–459. [PubMed]
8. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003;41:771–780. [PubMed]
9. van der Kooi AJ, Bonne G, Eymard B, Duboc D, Talim B, et al. Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. Neurology. 2002;59:620–623. [PubMed]
10. Sebillon P, Bouchier C, Bidot LD, Bonne G, Ahamed K, et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet. 2003;40:560–567. [PMC free article] [PubMed]
11. Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209–210. [PubMed]
12. Botto N, Vittorini S, Colombo MG, Biagini A, Paradossi U, et al. A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a ‘hot spot’ region at exon 3: a case report. Cardiovasc Ultrasound. 2010;8:9. [PMC free article] [PubMed]
13. Mestroni L, Taylor MR. Lamin A/C gene and the heart: how genetics may impact clinical care. J Am Coll Cardiol. 2008;52:1261–1262. [PMC free article] [PubMed]
14. Hutchison CJ, Alvarez-Reyes M, Vaughan OA. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J Cell Sci. 2001;114:9–19. [PubMed]
15. Wang H, Wang J, Zheng W, Wang X, Wang S, et al. Mutation Glu82Lys in lamin A/C gene is associated with cardiomyopathy and conduction defect. Biochem Biophys Res Commun. 2006;344:17–24. [PubMed]
16. Sagelius H, Rosengardten Y, Hanif M, Erdos MR, Rozell B, et al. Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J Cell Sci. 2008;121:969–978. [PubMed]
17. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet. 2005;14:155–169. [PubMed]
18. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007;21:55–62. [PubMed]
19. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284–1291. [PMC free article] [PubMed]
20. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97:4239–4244. [PubMed]
21. Feng JJ, Marston S. Genotype-phenotype correlations in ACTA1 mutations that cause congenital myopathies. Neuromuscul Disord. 2009;19:6–16. [PubMed]
22. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006;30:604–610. [PubMed]
23. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395–1403. [PubMed]
24. Wang Y, Herron AJ, Worman HJ. Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet. 2006;15:2479–2489. [PubMed]
25. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet. 2005;14:2167–2180. [PubMed]
26. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. J Struct Biol. 1998;122:42–66. [PubMed]
27. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, et al. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med. 2000;342:770–780. [PubMed]
28. Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol. 2002;3:575–585. [PubMed]
29. Hutchison CJ. Lamins: building blocks or regulators of gene expression? Nat Rev Mol Cell Biol. 2002;3:848–858. [PubMed]
30. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest. 2004;113:357–369. [PMC free article] [PubMed]
31. Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol. 2008;44:293–303. [PubMed]
32. Henriques-Pons A, de Oliveira GM. Is the FAS/FAS-L pathway a promising target for treating inflammatory heart disease? J Cardiovasc Pharmacol. 2009;53:94–99. [PubMed]
33. Wollert KC, Heineke J, Westermann J, Lüdde M, Fiedler B, et al. The cardiac FAS (APO-1/CD95) Receptor/FAS ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation. 2000;101:1172–1178. [PubMed]
34. Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, et al. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the FAS (CD95/Apo-1) receptor: FAS activation and apoptosis in hypoxic myocytes. Cardiovasc Res. 2002;54:611–623. [PubMed]
35. Barac YD, Zeevi-Levin N, Yaniv G, Reiter I, Milman F, et al. The 1,4,5-inositol trisphosphate pathway is a key component in FAS-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res. 2005;68:75–86. [PubMed]
36. Lee SD, Tzang BS, Kuo WW, Lin YM, Yang AL, et al. Cardiac FAS receptor-dependent apoptotic pathway in obese Zucker rats. Obesity (Silver Spring) 2007;15:2407–2415. [PubMed]
37. Anselmi A, Gaudino M, Baldi A, Vetrovec GW, Bussani R, et al. Role of apoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med (Hagerstown) 2008;9:227–232. [PubMed]
38. Bishopric NH, Andreka P, Slepak T, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol. 2001;1:141–150. [PubMed]
39. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci. 2001;69:2957–2964. [PubMed]
40. Narula J, Pandey P, Arbustini E, Haider N, Narula N, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 1999;96:8144–8149. [PubMed]
41. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94:2285–2296. [PubMed]
42. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995;27:291–305. [PubMed]
43. Andrés V, González JM. Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol. 2009;187:945–957. [PMC free article] [PubMed]
44. Juan F, Wei D, Xiongzhi Q, Ran D, Chunmei M, et al. The changes of the cardiac structure and function in cTnTR141W transgenic mice. Int J Cardiol. 2008;128:83–90. [PubMed]
45. Rottman JN, Ni G, Khoo M, Wang Z, Zhang W, et al. Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice. J Am Soc Echocardiogr. 2003;16:1150–1157. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science